Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCNKS.L Regulatory News (CNKS)

  • There is currently no data for CNKS

Board Changes

9 Dec 2020 07:00

RNS Number : 9884H
Cenkos Securities PLC
09 December 2020
 

 

Cenkos Securities plc

9 December 2020

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

Board changes

 

Jim Durkin has informed the Board that he intends to retire as Chief Executive. Jim returned to lead the business in 2019, at a very difficult time for UK stockbrokers and successfully kept the Company profitable, led the restructuring of the Board and further strengthened governance.

 

The Board is pleased to announce that subject to FCA approval, Julian Morse, currently Executive Director and Head of the Growth Companies Team will be appointed Chief Executive. Julian joined Cenkos in its first year of operations and was a founding member of the Growth Companies Team, which he has led since 2016 and which has grown and performed strongly since.

 

Jim will continue in his role as Chief Executive and as a Director of the Company until Julian's appointment has been approved by the FCA and will then remain with the Company for a short period in order to facilitate a smooth transition of leadership through to March 2021.

 

The Board is also pleased to announce that subject to FCA approval, Jeremy Osler, Co-Head of Corporate Finance & General Counsel, is being appointed an Executive Director on the Board, in addition to his current role. Jeremy qualified as a lawyer and practiced with Ashurst before joining J.P. Morgan Cazenove and latterly Hannam & Partners. He joined Cenkos in 2016.

 

The Board has endorsed a strategy and organisational structure, designed to deliver sustainable growth and build shareholder value over the next 3 years and beyond. This strategy focuses on the core strengths of Cenkos and utilising the breadth and depth of talent that exists throughout the Company to continue to deliver exceptional results for its clients.

 

Commenting on the Board changes, Jim Durkin said:

 

"I will be leaving the Company in very good shape and I have every confidence that Julian will leverage his 25+ years' experience in the City to successfully lead the Company with the expert help of Jeremy, Lisa and the rest of the Board and Executive Committee. Our offices in London and Edinburgh have led some of the most successful transactions during 2020 including the IPOs of FRP Advisory, Round Hill Music Royalty Fund, Calnex Solutions and HeiQ. Whilst I will be stepping down from the Board, I look forward to watching the Company progress and intend to remain a supportive shareholder."

 

Julian Morse said:

 

"I am very excited to be taking over as Chief Executive of Cenkos, at what is a pivotal time for stockbrokers in the UK. With our focus, in particular, on growth companies, and investment trusts, we are well positioned to take advantage of the positive macro trends towards equity markets. Cenkos has always been and will remain nimble and share the entrepreneurial instincts of many of our clients, which enables us to flourish in periods of change.

 

Our people are our key asset, and I would like to thank them for all their hard work so far this year. We are approaching the end of the year with real momentum and I look forward to us continuing to drive returns for all our stakeholders. "

 

Chairman, Lisa Gordon said: "This year has been intense, and the challenges of Covid-19 have been well documented. In our case, we have performed well in 2020 and it has reinforced the Board's belief that Cenkos is made up of outstanding people. The Board has a shared vision for the Company's culture and structure going forward, which will provide opportunities for personal and professional development throughout the firm and secure Cenkos' continued success."

 

--End--

For further information contact:

Cenkos Securities plcLisa Gordon - Chairman +44 20 7397 8900

Nominated AdviserSpark Advisory Partners Limited - Matt Davis +44 20 3368 3550

Public RelationsBuchanan Communications - David Rydell +44 07798 646021

 

Additional Information

 

In accordance with the AIM Rules, the following information required to be disclosed in relation to Jeremy Osler is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.

 

Full Name and age:

Jeremy Joseph Scott Osler aged 49

 

Current Directorships/Partnerships:

None

 

Previous Directorships/Partnerships:

Hannam & Partners LLP - LLP member resigned 18 March 2016

 

Current interest in the Company's share capital:

26,151 Ordinary shares of 1 pence held in an ordinary managed account.

65,515 Ordinary shares of 1 pence held in accordance with the terms and conditions of Company's Deferred Bonus Scheme.

8,274 Ordinary shares of 1 pence held through the Company's Share Incentive Plan.

Options over 44,698 Ordinary shares held under the Company's Save As You Earn Plan. These options are at 40.27pence. These options expire on 30 June 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOATPBPTMTIMBAM
Date   Source Headline
19th Feb 201810:00 amRNSForm 8.5 (EPT/NON-RI)
15th Feb 201811:26 amRNSEBT Share Purchase
15th Feb 20189:41 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20189:32 amRNSForm 8.5 (EPT/NON-RI)
6th Feb 20185:46 pmRNSHolding(s) in Company
6th Feb 201810:36 amRNSForm 8.5 (EPT/NON-RI)
5th Feb 20189:18 amRNSHolding(s) in Company
31st Jan 20189:37 amRNSFurther re Directorate Change
29th Jan 201810:49 amRNSHolding(s) in Company
29th Jan 201810:48 amRNSHolding(s) in Company
29th Jan 20189:37 amRNSForm 8.5 (EPT/NON-RI)
26th Jan 20181:59 pmRNSDirector/PDMR Shareholding
26th Jan 20187:00 amRNSEBT Share Purchase
25th Jan 20183:35 pmRNSTransaction in Own Shares
24th Jan 201810:31 amRNSForm 8.5 (EPT/NON-RI)
23rd Jan 201810:35 amRNSForm 8.5 (EPT/NON-RI)
22nd Jan 20189:35 amRNSForm 8.5 (EPT/NON-RI)
19th Jan 20189:58 amRNSForm 8.5 (EPT/NON-RI)
18th Jan 201810:00 amRNSForm 8.5 (EPT/NON-RI)
17th Jan 20189:28 amRNSForm 8.5 (EPT/NON-RI)
16th Jan 20189:50 amRNSForm 8.5 (EPT/NON-RI)
15th Jan 20189:34 amRNSForm 8.5 (EPT/NON-RI)
12th Jan 201811:11 amRNSForm 8.5 (EPT/NON-RI)
11th Jan 20189:18 amRNSForm 8.5 (EPT/NON-RI)
10th Jan 20189:23 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20189:44 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20189:44 amRNSForm 8.5 (EPT/NON-RI)
8th Jan 20189:49 amRNSForm 8.5 (EPT/NON-RI)
5th Jan 201810:18 amRNSForm 8.5 (EPT/NON-RI)
4th Jan 201810:55 amRNSForm 8.5 (EPT/NON-RI)
3rd Jan 20189:58 amRNSForm 8.5 (EPT/NON-RI)
28th Dec 201710:59 amRNSForm 8.5 (EPT/NON-RI)
27th Dec 201710:55 amRNSForm 8.5 (EPT/NON-RI)
15th Dec 20179:58 amRNSForm 8.5 (EPT/NON-RI)
14th Dec 201710:16 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 201710:13 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 20172:58 pmRNSEBT Share Purchase
8th Dec 20172:30 pmRNSDirector/PDMR Shareholding
8th Dec 201711:48 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 201711:38 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20171:20 pmRNSHolding(s) in Company
24th Nov 20177:00 amRNSDirector/PDMR Shareholding
22nd Nov 20177:00 amRNSDirector/PDMR Shareholding
16th Nov 20179:36 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20171:06 pmRNSDirector/PDMR Shareholding
15th Nov 20179:25 amRNSForm 8.5 (EPT/NON-RI)
13th Nov 20174:03 pmRNSFurther re Directorate Change
9th Nov 201710:44 amRNSForm 8.5 (EPT/NON-RI)
7th Nov 20175:08 pmRNSHolding(s) in Company
7th Nov 201710:25 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.